[go: up one dir, main page]

AU7467898A - Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy - Google Patents

Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy

Info

Publication number
AU7467898A
AU7467898A AU74678/98A AU7467898A AU7467898A AU 7467898 A AU7467898 A AU 7467898A AU 74678/98 A AU74678/98 A AU 74678/98A AU 7467898 A AU7467898 A AU 7467898A AU 7467898 A AU7467898 A AU 7467898A
Authority
AU
Australia
Prior art keywords
partial
signal
monoclonal antibodies
binding anti
clonal anergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74678/98A
Inventor
Jeffrey A Bluestone
Marcus R Clark
Michael S. Cole
Judith A. Smith
J. Yun Tso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of AU7467898A publication Critical patent/AU7467898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU74678/98A 1997-04-21 1998-04-21 Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy Abandoned AU7467898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4408497P 1997-04-21 1997-04-21
US60044084 1997-04-21
PCT/US1998/008029 WO1998047531A2 (en) 1997-04-21 1998-04-21 Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy

Publications (1)

Publication Number Publication Date
AU7467898A true AU7467898A (en) 1998-11-13

Family

ID=21930444

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74678/98A Abandoned AU7467898A (en) 1997-04-21 1998-04-21 Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy

Country Status (2)

Country Link
AU (1) AU7467898A (en)
WO (1) WO1998047531A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
ES2559763T3 (en) 2002-09-10 2016-02-15 Affimed Gmbh CD3 specific human antibody with immunosuppressive properties
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004091510A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
EP2397189B1 (en) 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Methods of modulating immunity
SI1716178T1 (en) * 2004-02-16 2010-11-30 Micromet Ag Less immunogenic binding molecules
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
SG177944A1 (en) * 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
ES2709672T3 (en) 2006-01-12 2019-04-17 Alexion Pharma Inc Antibodies for OX-2 / CD200 and uses thereof
MX2008015771A (en) 2006-06-14 2009-01-27 Macrogenics Inc Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity.
CA2668411C (en) 2006-11-02 2020-02-25 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
JP5721951B2 (en) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and uses thereof
US20100129361A1 (en) * 2007-05-01 2010-05-27 The Brigham And Women's Hospital Immunosuppression with antibody against itm2a
CA2696164C (en) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
CA2716919C (en) 2008-03-14 2015-01-20 Biocon Limited An anti-cd6 monoclonal antibody and use thereof
KR20210014224A (en) 2008-05-02 2021-02-08 악셀레론 파마 인코포레이티드 Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
PT2563813E (en) 2010-04-30 2015-11-26 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
EA201291328A1 (en) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт ANTIBODIES TO C3d FRAGMENT OF COMPONENT 3
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9932386B2 (en) 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
PL3024485T3 (en) 2013-07-23 2021-06-14 Biocon Limited APPLICATION OF AND BASED ON CD6 BINDING PARTNER
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
EP3060235B1 (en) 2013-10-25 2020-12-02 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3250588A1 (en) 2015-01-29 2017-12-06 Board of Trustees of Michigan State University Cryptic polypeptides and uses thereof
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP3463461A4 (en) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. METHODS OF TREATING GENERALIZED REFRACTORY SEVERE MYASTHENIA
AU2017344462B2 (en) 2016-10-21 2024-07-25 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
KR102576012B1 (en) 2017-07-27 2023-09-07 알렉시온 파마슈티칼스, 인코포레이티드 High Concentration Anti-C5 Antibody Formulation
KR20200070355A (en) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 Dosage and administration of anti-C5 antibodies for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS)
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
WO2019157342A1 (en) 2018-02-09 2019-08-15 Acceleron Pharma Inc. Methods for treating heterotopic ossification
ES2996257T3 (en) 2018-05-31 2025-02-12 Alexion Pharma Inc Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
EA202191189A1 (en) 2018-10-30 2021-08-06 Алексион Фармасьютикалс, Инк. Subcutaneous administration and dosage of antibodies to C5 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
AU2021237124A1 (en) * 2020-03-20 2022-09-15 Monash University Compositions and methods for treating lupus
KR20230005268A (en) 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 Anti-CD19 Antibodies and Uses Thereof
CN117425673A (en) 2021-04-09 2024-01-19 武田药品工业株式会社 Antibodies targeting complement factor D and their uses
US20220332822A1 (en) * 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
JP2024518776A (en) 2021-04-26 2024-05-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド Anti-adgre2 antibodies and uses thereof
CN117545774A (en) 2021-04-26 2024-02-09 米伦纽姆医药公司 anti-CLEC 12A antibodies and uses thereof
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same

Also Published As

Publication number Publication date
WO1998047531A2 (en) 1998-10-29
WO1998047531A3 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
AU7467898A (en) Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
AU7967294A (en) A monoclonal anti-human il-6 receptor antibody
IL128406A0 (en) Monoclonal antibodies
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
AU5958996A (en) Monoclonal antibodies for human mesenchymal stem cells
EP1032421A4 (en) Monoclonal human natural antibodies
AU1462300A (en) Human pan-hcv human monoclonal antibodies
EP0603735A3 (en) Monoclonal antibodies that define a unique antigen of human b-cell antigen receptor complex.
IL115232A0 (en) Monoclonal antibodies against colon carcinoma-associated antigens
AU2329897A (en) Monoclonal antibodies specific for the platelet derived growth factor beta receptor and methods of use thereof
IL175399A (en) Antibodies binding to ob receptor variants
HUP0202532A3 (en) Human monoclonal antibody against a costimulatory signal transduction molecule (ailim) and pharmaceutical use thereof
AU6916296A (en) Recombinant anti-cd4 antibodies for human therapy
AU5927398A (en) Fc receptors and polypeptides
AU5365296A (en) Human monoclonal antibody against lung carcinoma
AU1687500A (en) Antihuman vegf monoclonal antibody
AU5456698A (en) Binding agents specific for iga receptor
AU5196996A (en) Adhesion receptor antagonists
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU3587599A (en) Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
AU5937598A (en) Humanized anti-human Fas antibody
IL131136A0 (en) Spalpha:a novel scavenger receptor cysteine-rich domain-containing polypeptide and monoclonal antibodies thereto
PT725504E (en) RECEIVER RADIO WITH DEVICE FOR PRESENTATION OF RECEIVED DIGITAL TRANSIT INFORMATION
AU4256096A (en) Monoclonal antibody fragments having immunosuppressant activity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase